https://www.biopharmaapac.com/news/80/7788/ideaya-biosciences-advances-ide574-into-phase-1-as-first-patient-enrolled-for-kat6-and-kat7-dual-inhibitor.html
IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual...
IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor